Search results for: 'service market'

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...

This report is a thorough examination of the current and future face of therapy for neurodegenerative diseases, such as Alzheimer's and Parkinson's. It articulates important growth drivers (e.g., precision medicine, AI paradigm for diagnostics, and the transformational megatrends of aging populations) and barriers they will face (e.g., the nature o...

The report covers the clinical trial assessment for radiodiagnostics, including PET, SPECT, and radiopharmaceuticals, comprising Alpha therapy, Beta therapy, Auger Therapy, and Theranostics. The report covers the key players in each space and their contributions to the radiopharmaceuticals landscape.The report sheds light on technology innovations ...

This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...

Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers. This analysis e...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease, nephrology, and neurodegenerative disease. It hi...

The microbiome sector is a core component of the self-care movement, promoting proactive health behaviors. The gut microbiota is now recognized as an organ-like system that influences overall health and specific medical conditions, making continued advancement critical to enhancing well-being.The consumer wellness industry is evolving alongside gro...

Rare diseases pose a global burden to healthcare despite making up a very small fraction of the global disease landscape. Most treatment options for rare diseases focus on maintaining the disease symptoms, rather than a disease-modifying approach. To address this unmet need, RNA therapies are emerging as disease-modifying approaches addressing the ...

Europe’s life sciences sector is approaching a defining inflection point in 2026, as major regulatory and policy reforms converge to reshape pharma, diagnostics, life sciences IT, biotechnology, and the bioeconomy. Together, these frameworks open clear growth pathways across the value chain: the Clinical Trials Regulation (CTR) and European Health ...